FAG
TEVA icon

Fortitude Advisory Group’s Teva Pharmaceuticals TEVA Stock Holding History

Fortitude Advisory Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,396
Closed -$20K – 1171
2022
Q1 		$20K Buy
2,396
+1,586
+196% +$13.2K 0.01% 836
2021
Q4 		$6K Buy
+810
New +$7.31K ﹤0.01% 1160

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fortitude Advisory Group's TEVA Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 2,396 shares — an estimated $20K sold.

Fortitude Advisory Group first reported a position in TEVA in Q4 2021 and held it in 2 quarters. The position peaked at $20K in Q1 2022. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 2,396 Teva Pharmaceuticals shares in Q2 2022, an estimated $20K.
  • Fortitude Advisory Group first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Teva Pharmaceuticals position peaked at $20K in Q1 2022.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.